Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Tuesday, May 15, 2018

Growth Hormone (GH) Administration Increases the Metabolic Activity of the left Hippocampus in an Elder Patient with Cognitive Disorders

How could this research be applied to stroke? Followup on that will never occur since we have NO stroke leadership and NO stroke strategy.

 

Growth Hormone (GH) Administration Increases the Metabolic Activity of the left Hippocampus in an Elder Patient with Cognitive Disorders


 Jesús Devesa 1*, Iria Núñez 2, Carlos Agra 3, Alejandro Bejarano 2 and Pablo Devesa 4.
1 Scientific Direction. Medical Center Foltra. Travesía de Montouto 24. 15886-Teo. Spain; jesus.devesa@usc.es 2 Nuclear Medicine. Hospital HM Modelo. Virrey Osorio 30. 15011-Coruña. Spain; inunez@hmhospitales.com. 3 Neuropsychology. Medical Center Foltra. Travesía de Montouto 24. 15886-Teo. Spain; carlosagra80@gmail.com 4 Research and Development. Medical Center Foltra. Travesía de Montouto 24. 15886-Teo. Spain; pdevesap@gmail.com * Correspondence: jesus.devesa@usc.es; Tel.: +34-981-802-928

Abstract:  

1) Background: We analyzed, by PET-SCAN, how growth hormone (GH) might act on the brain of a not GH-deficient elder woman who suspected that she was developing Alzheimer's disease; 

2) Methods: After performing a first psychometric study (TAVEC verbal learning test), the metabolic activity of brain structures related to cognition, memory and behavior was analyzed by 18-F Fluorodeoxyglucose PET-SCAN. The patient was then treated with GH (0.4 mg/day) during three weeks and the last day under this treatment a new PET-SCAN was carried out. One month after commencing the treatment with GH a new TAVEC test was performed; 

3) Results: GH administration normalized the cognitive deficits observed in the first cognitive test and significantly (p < 0.025) increased (Voxel-Based Morphometry) the metabolic activity in the left hippocampus, left amygdala and left parahippocampus, but also in practically all brain cortical areas; 

4) Conclusions: This is the first study in which the effects of GH on the brain have been visualized in images. Our data confirm the positive effects of this hormone on cognition and memories; although they do not allow us to conclude whether GH administration may be useful in the early stages of Alzheimer's disease, they seem to be promising.
Keywords

No comments:

Post a Comment